Tenax is incorporated in Delaware.
Tenax’s headquarters are located at 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517.
The Company was originally formed under the name Rudmer, David & Associates, Inc. in 1967 and subsequently changed its name to Synthetic Blood International, Inc. and later changed its name to Oxygen Biotherapeutics, Inc. before becoming Tenax Therapeutics in September 2014.
Tenax’ predecessor company, Synthetic Blood International, began trading on the OTC markets on February 26, 1993. On January 13, 2010, Tenax (known at the time as Oxygen Biotherapeutics) uplisted to Nasdaq.
Tenax’s fiscal year ends on December 31.
Tenax is traded on Nasdaq, and its CUSIP number is 88032L605.
Issuer Direct serves as Tenax Therapeutics’ transfer agent.
Phone: +1.919.481.4000
Email: transfer@issuerdirect.com
Cherry Bekaert LLP.
WyrickRobins.
Tenax’s press releases can be viewed here.
Tenax’s SEC filings can be viewed here.